Overall, TFRC can be applied to predict immune phenotypes, molecular subtypes, and immune cell infiltration in PAAD, which, in turn, can create a basis for new immunotherapies for pancreatic cancer in the future. The gene discussed is TFRC; the disease is pancreatic adenocarcinoma.